Immutep (ASX:IMM) said the combination of its eftilagimod alfa drug candidate with Merck's anti-PD-1 therapy Keytruda and chemotherapy generated strong objective response rates (ORR) and disease control rates (DCR) in 51 evaluable patients with advanced or metastatic non-squamous non-small cell lung cancer, according to a Monday filing with the Australian bourse.
Based on data from the Insight-003 trial, the combination therapy achieved a nearly 62% ORR in 47 patients, up from the historical control of about 41%, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments